Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Marqeta Inc. Q1 2026 Earnings Call - Marqeta Hits GAAP Profitability as Non-Block Growth Surges 33%
Marqeta delivered a strong first quarter 2026, posting $166 million in net revenue, up 19% year-over-year, driven by a 33% surge in transaction volume. The company achieved its first GAAP net income o...
- Marqeta reported Q1 2026 net revenue of $166 million, up 19% year-over-year, with gross profit reaching $118 million, also up 19%. Transaction volume grew 33% to $112 billion, marking the second consecutive quarter with TPV exceeding $100 billion. The company achieved its first GAAP net income of $8 million, with adjusted EBITDA surging 66% to $33 million and a 20% margin. Block's revenue concentration fell to 42%, as non-Block business grew at twice the pace, indicating successful customer diversification. Twelve of Marqeta's top 15 customers now operate in multiple countries, highlighting strong demand for multinational card issuing capabilities. BNPL growth remained robust at nearly 60% year-over-year, while expense management grew over 40%, driven by existing customer expansion. Management reiterated full-year net revenue guidance of 12-14% growth but lifted full-year adjusted EBITDA growth to the mid-to-high twenties%. Marqeta expects to be at GAAP breakeven in Q2 2026, with full-year net income guidance increased by $5 million to approximately $15 million. Block's new issuance decline is being pushed into the second half of the year, reducing the full-year gross profit headwind to 1.5 percentage points. The company is exploring stablecoin-backed card programs and agentic payment use cases, positioning its flexible credential technology for emerging fintech trends.
- company_name
- quarter
- +7 more takeaways
Arcus Biosciences Q1 2026 Earnings Call - Casdatifan Takes Center Stage in Kidney Cancer Push
Arcus Biosciences is pivoting hard into a new era of fully owned, late-stage development with casdatifan as the undisputed centerpiece. The company is accelerating enrollment in its phase III PEAK-1 k...
- 1. Full ownership of casdatifan marks a strategic inflection point for Arcus, eliminating partnership dependencies and allowing full control over development and commercialization.
- 2. Phase III PEAK-1 enrollment is accelerating and on track to complete by year-end 2026, targeting the IO-experienced second-line setting with a clear path to establish casdatifan plus cabozantinib as the new standard of care.
- 3. Management emphasizes casdatifan’s superior pharmacodynamic profile over belzutifan, citing sustained HIF-2 inhibition that translates to longer progression-free survival and higher response rates.
- +9 more takeaways
DHI Group Q1 2026 Earnings Call - ClearanceJobs Growth Offsets Tech Hiring Slowdown
DHI Group reported a mixed but strategically focused first quarter for 2026. ClearanceJobs drove the headline performance with 5% revenue growth and 7% bookings growth, buoyed by a $1 trillion U.S. de...
- ClearanceJobs revenue grew 5% year-over-year to $14.0 million, while bookings increased 7% to $18.0 million, highlighting the platform's role as the company's primary growth engine.
- The acquisition of Point Solutions Group (PSG) contributed $700,000 in revenue and bookings in its first partial quarter, with management projecting a full-year revenue uplift of approximately $6 million.
- Defense budget tailwinds are accelerating; the $1 trillion U.S. defense budget and NATO's 5% GDP spending targets are driving improved customer sentiment and demand for cleared tech talent.
- +7 more takeaways
Solventum Technologies Q1 2026 Earnings Call - Momentum and Margin Expansion Outpace Separation Headwinds
Solventum kicked off fiscal 2026 with a quarter that defied the noise. The company delivered organic sales growth and EPS that beat both plan and consensus, proving that the commercial engine is firin...
- Organic sales grew 2.1% in Q1 2026, beating expectations and setting a strong tone for the full year.
- EPS came in at $1.48, representing 11% growth and landing ahead of consensus.
- Gross margins expanded by 80 basis points year-over-year to 56.4%, driven by favorable mix, sales leverage, and programmatic savings.
- +7 more takeaways
Rapid7 Q1 2026 Earnings Call - AI-Driven Security Shift Fuels Core Platform Growth
Rapid7 delivered outperformance across all guided metrics in Q1 2026, with ARR of $832 million and non-GAAP operating income of $24 million, driven by sustained growth in its core Detection and Respon...
- Rapid7 exceeded Q1 2026 guidance, reporting $832 million in ARR and $24 million in non-GAAP operating income, with strong free cash flow of $33 million.
- Core platform solutions (D&R and Exposure Management) now represent over 80% of ARR, with D&R growth accelerating to 7% year-over-year, driven by MDR strength.
- The acquisition of Kenzo Security introduces an agentic AI platform that automates security operations, shifting focus from manual alert investigation to machine-speed remediation at scale.
- +7 more takeaways
Myriad Genetics Q1 2026 Earnings Call - Hereditary Cancer Growth Fuels Confidence as MRD and FirstGene Launches Set Stage for 2026 Acceleration
Myriad Genetics reported Q1 2026 revenue of $200.4 million, landing in line with guidance, driven by double-digit volume growth in hereditary cancer testing and strong momentum in its mental health fr...
- Q1 2026 revenue came in at $200.4 million, within the low end of the $200-$202 million guidance range, representing 2% year-over-year growth.
- Hereditary cancer testing volume surged 14% year-over-year, with the unaffected population growing 16% and the affected population growing 10%, outpacing market rates.
- GeneSight mental health test revenue jumped 24% year-over-year to $38.3 million, supported by 7% volume growth and improved reimbursement dynamics from biomarker legislation.
- +7 more takeaways
Dentsply Sirona Q1 2026 Earnings Call - Return to Growth Plan Faces Headwinds Amid Tariffs and Execution Shifts
Dentsply Sirona reported Q1 2026 revenue of $880 million, essentially flat on a reported basis but down 6.7% on a constant currency basis. The decline was driven by tough comps, tariff impacts, and a ...
- Q1 2026 revenue came in at $880 million, up 0.1% as reported but down 6.7% on a constant currency basis, reflecting tough comps, tariff headwinds, and a one-time institutional installation in the prior year.
- Adjusted EBITDA margins contracted 430 basis points, driven by a 560 basis point gross margin decline from lower volumes, unfavorable sales mix, and tariff impacts.
- Operating expenses fell by $20 million on a constant currency basis, signaling early progress in the Return to Growth action plan’s cost restructuring efforts.
- +7 more takeaways
Talen Energy Q1 2026 Earnings Call - Cornerstone Acquisition Financing Locked In, 2027/2028 FCF Per Share Outlook Raised
Talen Energy reported a strong first quarter of 2026, with adjusted EBITDA more than doubling and adjusted free cash flow quadrupling year-over-year, driven by the recent acquisition of Freedom and Gu...
- Q1 2026 Adjusted EBITDA reached $473 million and adjusted free cash flow hit $350 million, with year-over-year growth more than doubling and quadrupling respectively, driven by the Freedom and Guernsey acquisitions and higher market prices.
- Talen Energy secured $4 billion in senior unsecured notes for the pending Cornerstone acquisition, reducing the cost of capital and allowing the company to close the deal once regulatory approvals are finalized.
- The company reaffirmed its 2026 guidance, with adjusted EBITDA expected between $1.75 billion and $2.05 billion and adjusted free cash flow between $980 million and $1.18 billion, excluding Cornerstone.
- +7 more takeaways
GRAIL Q1 2026 Earnings Call - Galleri Volume Surges 50% Amid Epic Integration and ASCO Data Anticipation
GRAIL reported strong first quarter 2026 results, with Galleri test volumes jumping 50% year-over-year to over 56,000 tests and screening revenue climbing 37% to $39.8 million. The company continues t...
- Galleri test volumes surged 50% year-over-year in Q1 2026, surpassing 56,000 tests, while screening revenue grew 37% to $39.8 million.
- Total revenue reached $40.8 million, up 28% year-over-year, driven by a 37% increase in screening revenue and $1 million in development services.
- Net loss improved 12% to $93.2 million, with adjusted EBITDA narrowing 19% to negative $79.9 million, reflecting improved operational leverage.
- +7 more takeaways
"Hinge Health" Q1 2026 Earnings Call - Strong Q1 Results, Raised Guidance, and Migraine Program Launch
Hinge Health delivered a strong start to 2026, with Q1 revenue of $182 million, up 47% year-over-year, significantly beating guidance. The company raised its full-year revenue guidance to $798-$804 mi...
- Revenue of $182 million in Q1 2026, up 47% year-over-year, significantly exceeding the guidance range of $171-$173 million.
- LTM calculated billings reached $770 million, a 52% year-over-year increase, driven by higher eligible lives and improved member yields.
- Gross margin expanded to 85% from 81% in Q1 2025, reflecting AI-driven care team efficiency and hardware optimization.
- +12 more takeaways